Pfizer and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals.
Pfizer has turned $1 billion into $35 million.
The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
Astellas treatment offers new hope to a devastated rare disease community
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
